Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Abbott

3 High Dividend Growth Kings for Generations of Income That Are Still Rated ‘Buy’

These 3 Dividend Kings combine steady businesses, rising dividends, and solid upside potential for long-term income investors.

Barchart

This Dividend King With a 54-Year Dividend Streak Is Down 13% YTD. Time to Buy the Dip?

This Dividend King is suddenly on sale. Should you buy the dip?

Barchart

Patients alarmed after glucose monitors used by diabetics are recalled after links to 7 deaths

Abbott recalled certain sensors used in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warning they could produce falsely low glucose readings

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Know About Recent FDA Alerts Involving Glucose Monitors in 2026

For millions living with diabetes, a continuous glucose monitor (CGM) is more than technology. It is a lifeline that provides safety in an unpredictable world. These devices allow you to sleep without fear and eat without complex math. However, high-level FDA alerts can vanish that sense of security instantly. False…

Budget and the Bees

Coworkers of different generations mentor each other to reduce workplace misunderstandings

With at least five generations participating in the U.S. workforce, coworkers can at times feel like they speak different languages

The Independent UK

New implant for heart failure patients to be rolled out across the NHS

The British Heart Foundation estimates that more than a million people in the UK are living with heart failure

The Independent UK

Do Wall Street Analysts Like Abbott Laboratories Stock?

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?

Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.

Barchart

Is Abbott’s January Pullback a Good Time to Buy?

Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its business and driving cash flow.

MarketBeat

How Authentic Was Abbott Elementary In Relocating The Cast To An Abandoned Mall? Janelle James Opened Up About ‘Lots Of Smells’

At least the animatronic Ben Franklin head is dead!

Cinemablend

2 Healthcare Names That Could Get a Big Boost From Earnings

Both Abbott Laboratories and Intuitive Surgical report fourth-quarter results in late January—and both companies offer investors multiple reasons to be bullish.

MarketBeat

Fortune 500 exec: College grads aren't ready for today's jobs

There's a missing link between college and career.

Fortune

With Abbott Elementary Nominated For Major Awards, The Stars Opened Up About Representing Traditional Sitcoms Against Streaming Competition

Will Abbott Elementary score in the awards circuit this year?

Cinemablend

This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now?

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength

Broadcom, Abbott, and Nordic American raised dividends, offering strong yields and long-term upside despite market volatility and sector headwinds.

Cinemablend

Abbott Elementary's Mid-Season Finale Featured Its Craziest Plot Twist, And I Can't Stop Thinking About The Silly Repercussions It Could Have

I cannot believe this really happened!

Benzinga

FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

Euronews

Faulty glucose monitors linked to 7 deaths and more than 700 injuries worldwide. Here’s what we know

The sensors provide real-time measurements of sugar levels in the blood, sending that data wirelessly to a device or phone.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns

The U.S. Food and Drug Administration warned people to stop using certain types of glucose monitor sensors that were linked to seven deaths

The Independent UK

7 deaths linked to faulty glucose monitors put in people’s arms, FDA says

About three million devices are affected, though many may be expired or already used

Barchart

Is Abbott Laboratories Stock Underperforming the S&P 500?

Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Benzinga

How This 'Hidden Gold Mine' Has Beaten The Market For 30 Years

For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes.

Benzinga

Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle

For the previous edition of Deal Dispatch, click here.

Woman & Home

Our fashion team has been hunting Black Friday fashion deals for years – here are the 24 items we really rate

Plenty of brands have already dropped major Black Friday discounts, and these are items worth shopping right now

Barchart

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.